Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that pharmacy and therapeutics committee members anticipate that Basilea/Johnson & Johnson's ceftobiprole and Theravance/Astellas's telavancin are highly likely to be included on formulary as emerging anti-methicillin- resistant Staphylococcus aureus (MRSA) agents. Ceftobiprole, the first anti- MRSA cephalosporin to enter the market, will be used primarily as a first-line agent, and twice-daily dosing will not limit its uptake. More than 60% of infectious disease specialists and critical care specialists plan to use ceftobiprole as a first-line antibiotic. Those surveyed expect telavancin to be included on formulary, although the majority says that there will be restrictions on the use of this novel anti-MRSA antibiotic. Telavancin will be used primarily for the treatment of hospital-acquired pneumonia, skin and soft tissue infections and bloodstream infections. Both physician groups agree that telavancin would take away most prescriptions from vancomycin, followed by Pfizer's Zyvox.
The new Physician & Payer Forum primary market research report entitled Hospital Anti-Infectives: Formulary Inclusion and Uptake of Novel Antibacterials, Antifungals, and Biologic Therapies also finds that surveyed pharmacy and therapeutics committee members do not view major differences between the echinocandins: Merck's Cancidas, Pfizer's Eraxis and Astellas's Mycamine. In contrast, surveyed clinicians voice a preference for Cancidas in the treatment of invasive candidiasis. Additionally, surveyed clinicians view decreasing levels of Staphylococcus aureus susceptibility to vancomycin as the most concerning drawback of this antibiotic. With the launch of novel glycopeptides and anti-MRSA cephalosporins, they expect significant changes in usage.
"Infectious disease and critical care specialists expect that novel glycopeptides and anti-MRSA cephalosporins will replace 25% of their vancomycin usage once these agents become available," according to Sylvia Eash, Ph.D., analyst at Decision Resources. "The new agents will also have an impact on other branded antibiotics, such as Zyvox, but to a lesser extent."
Hospital Anti-Infectives: Formulary Inclusion and Uptake of Novel Antibacterials, Antifungals, and Biologic Therapies is based on a U.S. survey of 52 infectious disease specialists, 49 critical care specialists, and an additional 22 infectious disease specialists who sit on their hospital pharmacy and therapeutics committee. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors. The report analyzes the drivers of hospital anti- infective formulary inclusion, perceptions and dynamics of hospital antifungal and antibacterial brands, and receptivity to emerging therapies and new product profiles.
About Physician & Payer Forum
Physician & Payer Forum is a primary research service from Decision Resources that offers access to high volume-prescribing physicians, specialists, and managed care organization representatives in the United States; analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications of events and issues for the pharmaceutical market.
About Decision Resources
Decision Resources, Inc., (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
SOURCE: Decision Resources
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
Web site: http://www.decisionresources.com/